LYNDHURST, N.J., July 5 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, has completed the previously announced acquisition
of Focus Diagnostics, Inc., in a cash transaction valued at approximately $185
million.
Focus Diagnostics is recognized worldwide for its leadership in infectious
and immunologic diseases and has established a reputation for being first to
introduce new assays to the market, including diagnostic tests for Lyme
disease, West Nile Virus and SARS. In addition, Focus Diagnostics develops and
markets diagnostic products, such as HerpeSelect(R) for Herpes Simplex Virus.
The acquisition is not expected to have a material impact on Quest
Diagnostics' 2006 earnings per share, excluding anticipated charges associated
with the transaction.
About Quest Diagnostics
Quest Diagnostics is the leading provider of diagnostic testing,
information and services that patients and doctors need to make better
healthcare decisions. The company offers the broadest access to diagnostic
testing services through its national network of laboratories and patient
service centers, and provides interpretive consultation through its extensive
medical and scientific staff. Quest Diagnostics is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is
available at: http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2005 Form 10-K and subsequent SEC filings.
SOURCE Quest Diagnostics Incorporated
CONTACT:
Investors: Laure Park, +1-201-393-5030;
Media: Gary Samuels,
+1-201-393-5700, both for Quest Diagnostics